|
[1]ROTMAN Y, SANYAL AJ.Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease[J].Gut, 2017, 66 (1) :180-190
|
|
[2]DING YP, LI H, ZHANG W, et al.Epidemiological characteristics of nonalcoholic fatty liver disease with elevated alanine aminotransferase and related risk factors[J].J Clin Hepatol, 2017, 33 (12) :2355-2360. (in Chinese) 丁玉平, 李海, 张文, 等.ALT升高的非酒精性脂肪性肝病的流行病学特征及其危险因素分析[J].临床肝胆病杂志, 2017, 33 (12) :2355-2360.
|
|
[3]BETRAPALLY NS, GILLEVET PM, BAJAJ JS.Gut microbiome and liver disease[J].Transl Res, 2017, 179:49-59.
|
|
[4]YI YR, ZENG Y, HE J, et al.Changes of intestinal flora in patients with non-alcoholic fatty liver disease and the effects of bifidobacterium triple viable capsules on intestinal flora, liver function, blood lipid and insulin resistance[J/CD].Chin J Liver Dis:Electronic Edition, 2016, 8 (3) :87-92. (in Chinese) 易艳容, 曾亚, 何佳, 等.非酒精性脂肪性肝病患者肠道菌群变化及双歧杆菌三联活菌胶囊对肠道菌群、肝功能、血脂及胰岛素抵抗的影响[J/CD].中国肝脏病杂志:电子版, 2016, 8 (3) :87-92.
|
|
[5]MRIDHA AR, WREE A, ROBERTSON AAB, et al.NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice[J].J Hepatol, 2017, 66 (5) :1037-1046.
|
|
[6]DAY CP, JAMES OF.Steatohepatitis:a tale of two"hits"?[J].Gastroenterology, 1998, 114 (4) :842-845.
|
|
[7]LEUNG JC, LOONG TC, WEI JL, et al.Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients[J].Hepatology, 2017, 65 (1) :54-64.
|
|
[8]BELLANTI F, VILLANI R, TAMBORRA R, et al.Synergistic interaction of fatty acids and oxysterols impairs mitochondrial function and limits liver adaptation during nafld progression[J].Redox Biol, 2017, 15:86-96.
|
|
[9]TILG H, MOSCHEN AR.Evolution of inflammation in nonalcoholic fatty liver disease:The multiple parallel hits hypothesis[J].Hepatology, 2010, 52 (5) :1836-1846.
|
|
[10]SENDER R, FUCHS S, MILO R.Are we really vastly outnumbered?Revisiting the ratio of bacterial to host cells in humans[J].Cell, 2016, 164 (3) :337-340.
|
|
[11]ZHERNAKOVA A, KURILSHIKOV A, BONDER MJ, et al.Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity[J].Science, 2016, 352 (6285) :565-569.
|
|
[12]TANCA A, ABBONDIO M, PALOMBA A, et al.Potential and active functions in the gut microbiota of a healthy human cohort[J].Microbiome, 2017, 5 (1) :79.
|
|
[13]JUMPERTZ R, LE DS, TURNBAUGH PJ, et al.Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans[J].Am J Clin Nutr, 2011, 94 (1) :58-65.
|
|
[14] BOURSIER J, MUELLER O, BARRET M, et al.The severity of NAFLD is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota[J].Hepatology, 2016, 63 (3) :764-775.
|
|
[15]LE RT, LLOPIS M, LEPAGE P, et al.Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice[J].Gut, 2013, 62 (12) :1787-1794.
|
|
[16]HENAOMEJIA J, ELINAV E, JIN C, et al.Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity[J].Nature, 2012, 482 (7384) :179-185.
|
|
[17]XIE G, WANG X, LIU P, et al.Distinctly altered gut microbiota in the progression of liver disease[J].Oncotarget, 2016, 7 (15) :19355-19366.
|
|
[18]DRENICK EJ, FISLER J, JOHNSON D.Hepatic steatosis after intestinal bypass—prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition[J].Gastroenterology, 1982, 82 (3) :535-548.
|
|
[19]SHANAB AA, SCULLY P, CROSBIE O, et al.Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis:association with toll-like receptor 4 expression and plasma levels of interleukin 8[J].Dig Dis Sci, 2011, 56 (5) :1524-1534.
|
|
[20]ZENG QF, YANG GL, WANG CF.Application of probiotics in treatment of liver diseases[J].Chin J Immunol, 2016, 32 (11) :1711-1714. (in Chinese) 曾庆丰, 杨桂连, 王春凤.益生菌在肝脏疾病方面的应用[J].中国免疫学杂志, 2016, 32 (11) :1711-1714.
|
|
[21]BOURSIER J, MUELLER O, BARRET M, et al.The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota[J].Hepatology, 2016, 63 (3) :764-775.
|
|
[22]BCKHED F, DING H, WANG T, et al.The gut microbiota as an environmental factor that regulates fat storage[J].Proc Natl Acad Sci U S A, 2004, 101 (44) :15718-15723.
|
|
[23]BOLOGNINI D, TOBIN AB, MILLIGAN G, et al.The pharmacology and function of receptors for short-chain fatty acids[J].Mol Pharmacol, 2016, 89 (3) :388-398.
|
|
[24]MATSUSHITA N, OSAKA T, HARUTA I, et al.Effect of lipopolysaccharide on the progression of non-alcoholic fatty liver disease in high caloric diet-fed mice[J].Scand J Immunol, 2016, 83 (2) :109-118.
|
|
[25]KIZILTAS S.Toll-like receptors in pathophysiology of liver diseases[J].World J Hepatol, 2016, 8 (32) :1354-1369.
|
|
[26]HUANG K, DU M, TAN X, et al.PARP1-mediated PPARαpoly (ADP-ribosyl) ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease[J].J Hepatol, 2017, 66 (5) :962-977.
|
|
[27]COPE K, RISBY T, DIEHL AM.Increased gastrointestinal ethanol production in obese mice:Implications for fatty liver disease pathogenesis[J].Gastroenterology, 2000, 119 (5) :1340-1347.
|
|
[28]NAIR S, COPE K, RISBY TH, et al.Obesity and female gender increase breath ethanol concentration:Potential implications for the pathogenesis of nonalcoholic steatohepatitis[J].Am J Gastroenterol, 2001, 96 (4) :1200-1204.
|
|
[29]HE CX, XU ZJ, FAN JG.Endogenous alcohol in non-alcoholic fatty liver disease[J].J Pract Hepatol, 2016, 19 (1) :109-112. (in Chinese) 何崇信, 徐正婕, 范建高.内生性乙醇与非酒精性脂肪性肝病研究进展[J].实用肝脏病杂志, 2016, 19 (1) :109-112.
|
|
[30]DUPARC T, PLOVIER H, MARRACHELLI VG, et al.Hepatocyte My D88 affects bile acids, gut microbiota and metabolome contributing to regulate glucose and lipid metabolism[J].Gut, 2017, 66 (4) :620-632.
|
|
[31]JIAO N, BAKER SS, CHAPARODRIGUEZ A, et al.Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD[J].Gut, 2017, 152 (5) :s1068.
|
|
[32]MOUZAKI M, WANG AY, BANDSMA R, et al.Bile acids and dysbiosis in non-alcoholic fatty liver disease[J].PLo S One, 2016, 11 (5) :e0151829.
|
|
[33]CHEN YM, LIU Y, ZHOU RF, et al.Associations of gut-floradependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults[J].Sci Rep, 2016, 8 (6) :19076.
|
|
[34]SPENCER MD, HAMP TJ, REID RW, et al.Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency[J].Gastroenterology, 2011, 140 (3) :976-986.
|
|
[35]TANG YL, QIU DK, MA X.Interaction between Th17 cells and steatotic hepatocytes in nonalcoholic fatty liver disease[J].Chin Hepatol, 2010, 15 (2) :105-108. (in Chinese) 汤艳丽, 邱德凯, 马雄.Th17细胞与肝细胞脂肪变性的相互作用初探[J].肝脏, 2010, 15 (2) :105-108.
|
|
[36]SCHIRMER M, SMEEKENS SP, VLAMAKIS H, et al.Linking the human gut microbiome to inflammatory cytokine production capacity[J].Cell, 2016, 167 (4) :1125-1136.
|
|
[37]MA C, KESARWALA AH, EGGERT T, et al.NAFLD causes selective CD4+T lymphocyte loss and promotes hepatocarcinogenesis[J].Nature, 2016, 531 (7593) :253-257.
|
|
[38]SAYIN SI, WAHLSTRM A, FELIN J, et al.Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-betamuricholic acid, a naturally occurring FXR antagonist[J].Cell Metab, 2013, 17 (2) :225-235.
|
DownLoad: